---
title: "PIK3CA E545A in MCF-7 Cells: Increased Proliferation and Reduced Sensitivity to Alpelisib"
id: "pubmed-42341421"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42341421"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42341421/"
doi: "10.1016/j.bbrc.2026.154189"
published_at: "2026-09-03T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PIK3CA E545A in MCF-7 Cells: Increased Proliferation and Reduced Sensitivity to Alpelisib
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42341421
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42341421/)
- **DOI:** [10.1016/j.bbrc.2026.154189](https://doi.org/10.1016%2Fj.bbrc.2026.154189)
- **Published At:** 2026-09-03T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The study generated an isogenic MCF-7 breast cancer cell line carrying the **PIK3CA E545A** mutation using **CRISPR/Cas9**-mediated homology-directed repair to evaluate functional and therapeutic effects. - E545A produced a clear gain-of-function phenotype with a mesenchymal-like morphological change, including reduced circularity and decreased cell size compared with wild-type controls. - Mutant cells showed enhanced tumor cell fitness: faster proliferation kinetics, increased metabolic activity, and markedly higher clonogenic capacity relative to parental MCF-7 cells. - Growth curves demonstrated a persistent and stable proliferative advantage of E545A cells across all measured time points. - E545A reduced cellular sensitivity to the PI3Kα inhibitor **Alpelisib**; mutant cells maintained migratory capacity under treatment and exhibited a time-dependent increase in IC50 consistent with adaptive resistance. - The findings indicate that the noncanonical E545A variant is functionally active and has therapeutic consequences, expanding understanding of PIK3CA-driven oncogenic diversity beyond canonical hotspot mutations. - The authors emphasize the potential need for variant-resolved stratification when considering PI3K-targeted therapies in hormone receptor–positive, HER2–negative breast cancer.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42341421/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42341421%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42341421/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42341421/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42341421/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42341421/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42341421/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42341421/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42341421%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42341421%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42341421/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42341421/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42341421/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42341421/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0006-291X\(26\)00953-8 "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42341421/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42341421/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42341421/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42341421/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42341421/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42341421/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42341421/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42341421/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42341421/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42341421/#linkout) Title & authors Abstract Conflict of interest statement Similar articles MeSH terms Substances Related information LinkOut - more resources Biochem Biophys Res Commun Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biochem+Biophys+Res+Commun%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Biochem+Biophys+Res+Commun%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42341421/) . 2026 Sep 3:829:154189. doi: 10.1016/j.bbrc.2026.154189. Epub 2026 Jun 24. # Functional characterization of PIK3CA E545A mutation in MCF-7 breast cancer cells reveals enhanced proliferation and resistance to Alpelisib [Hoai Thu Le](https://pubmed.ncbi.nlm.nih.gov/?term=Le+HT&cauthor_id=42341421)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#full-view-affiliation-1 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: lethuhoai@ump.edu.vn."), [Nguyen Bao Nghi](https://pubmed.ncbi.nlm.nih.gov/?term=Nghi+NB&cauthor_id=42341421)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#full-view-affiliation-2 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: nbnghi@ump.edu.vn."), [Vu Diem My](https://pubmed.ncbi.nlm.nih.gov/?term=My+VD&cauthor_id=42341421)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#full-view-affiliation-3 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: diemmyvu@ump.edu.vn."), [Hoang Anh Vu](https://pubmed.ncbi.nlm.nih.gov/?term=Vu+HA&cauthor_id=42341421)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#full-view-affiliation-4 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: hoanganhvu@ump.edu.vn."), [Ma Chi Thanh](https://pubmed.ncbi.nlm.nih.gov/?term=Thanh+MC&cauthor_id=42341421)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#full-view-affiliation-5 "School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: mcthanh@ump.edu.vn."), [Bui Minh Tri](https://pubmed.ncbi.nlm.nih.gov/?term=Tri+BM&cauthor_id=42341421)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#full-view-affiliation-6 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: buiminhtri17041992@gmail.com."), [Vo Van Thanh Niem](https://pubmed.ncbi.nlm.nih.gov/?term=Niem+VVT&cauthor_id=42341421)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#full-view-affiliation-7 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: thanhniem2611@gmail.com."), [Huynh Anh Phuong](https://pubmed.ncbi.nlm.nih.gov/?term=Phuong+HA&cauthor_id=42341421)[ 8 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#full-view-affiliation-8 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: huynhanhphuong0803@gmail.com.") Affiliations Expand ### Affiliations * 1 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: lethuhoai@ump.edu.vn. * 2 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: nbnghi@ump.edu.vn. * 3 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: diemmyvu@ump.edu.vn. * 4 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: hoanganhvu@ump.edu.vn. * 5 School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: mcthanh@ump.edu.vn. * 6 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: buiminhtri17041992@gmail.com. * 7 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: thanhniem2611@gmail.com. * 8 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: huynhanhphuong0803@gmail.com. * PMID: **42341421** * DOI: [ 10.1016/j.bbrc.2026.154189 ](https://doi.org/10.1016/j.bbrc.2026.154189) Item in Clipboard # Functional characterization of PIK3CA E545A mutation in MCF-7 breast cancer cells reveals enhanced proliferation and resistance to Alpelisib Hoai Thu Le et al. Biochem Biophys Res Commun. 2026. Show details Display options Display options Format Abstract PubMed PMID Biochem Biophys Res Commun Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biochem+Biophys+Res+Commun%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Biochem+Biophys+Res+Commun%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42341421/) . 2026 Sep 3:829:154189. doi: 10.1016/j.bbrc.2026.154189. Epub 2026 Jun 24. ### Authors [Hoai Thu Le](https://pubmed.ncbi.nlm.nih.gov/?term=Le+HT&cauthor_id=42341421)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#short-view-affiliation-1 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: lethuhoai@ump.edu.vn."), [Nguyen Bao Nghi](https://pubmed.ncbi.nlm.nih.gov/?term=Nghi+NB&cauthor_id=42341421)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#short-view-affiliation-2 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: nbnghi@ump.edu.vn."), [Vu Diem My](https://pubmed.ncbi.nlm.nih.gov/?term=My+VD&cauthor_id=42341421)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#short-view-affiliation-3 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: diemmyvu@ump.edu.vn."), [Hoang Anh Vu](https://pubmed.ncbi.nlm.nih.gov/?term=Vu+HA&cauthor_id=42341421)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#short-view-affiliation-4 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: hoanganhvu@ump.edu.vn."), [Ma Chi Thanh](https://pubmed.ncbi.nlm.nih.gov/?term=Thanh+MC&cauthor_id=42341421)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#short-view-affiliation-5 "School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: mcthanh@ump.edu.vn."), [Bui Minh Tri](https://pubmed.ncbi.nlm.nih.gov/?term=Tri+BM&cauthor_id=42341421)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#short-view-affiliation-6 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: buiminhtri17041992@gmail.com."), [Vo Van Thanh Niem](https://pubmed.ncbi.nlm.nih.gov/?term=Niem+VVT&cauthor_id=42341421)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#short-view-affiliation-7 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: thanhniem2611@gmail.com."), [Huynh Anh Phuong](https://pubmed.ncbi.nlm.nih.gov/?term=Phuong+HA&cauthor_id=42341421)[ 8 ](https://pubmed.ncbi.nlm.nih.gov/42341421/#short-view-affiliation-8 "Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: huynhanhphuong0803@gmail.com.") ### Affiliations * 1 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: lethuhoai@ump.edu.vn. * 2 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: nbnghi@ump.edu.vn. * 3 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: diemmyvu@ump.edu.vn. * 4 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: hoanganhvu@ump.edu.vn. * 5 School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: mcthanh@ump.edu.vn. * 6 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: buiminhtri17041992@gmail.com. * 7 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: thanhniem2611@gmail.com. * 8 Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. Electronic address: huynhanhphuong0803@gmail.com. * PMID: **42341421** * DOI: [ 10.1016/j.bbrc.2026.154189 ](https://doi.org/10.1016/j.bbrc.2026.154189) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract PIK3CA mutations are central oncogenic drivers in hormone receptor-positive, HER2-negative breast cancer; however, the functional and therapeutic relevance of noncanonical variants remains incompletely defined. The E545A mutation, increasingly reported in specific patient populations, has not been systematically investigated. We generated an isogenic MCF-7 cell model harboring the PIK3CA E545A mutation using CRISPR/Cas9-mediated homology-directed repair to delineate its phenotypic and pharmacological consequences. E545A induced a robust gain-of-function phenotype, characterized by a mesenchymal-like morphological transition with reduced circularity and decreased cell size. This structural shift was accompanied by enhanced tumor cell fitness, including accelerated proliferation kinetics, increased metabolic activity, and significantly elevated clonogenic capacity compared with wild-type controls. Notably, growth trajectories showed sustained divergence between mutant and control cells across all time points, indicating a stable proliferative advantage. Importantly, E545A conferred diminished sensitivity to the PI3Kα inhibitor Alpelisib. Mutant cells retained migratory capacity under treatment and exhibited a pronounced, time-dependent increase in IC50, consistent with adaptive resistance. Collectively, these findings identify E545A as a functionally active and therapeutically consequential PIK3CA variant. Our study expands the current understanding of PIK3CA-driven oncogenic diversity beyond canonical hotspot mutations and underscores the need for variant-resolved stratification to improve the efficacy of PI3K-targeted therapies. **Keywords:** Alpelisib; Breast cancer; CRISPR/Cas9; E545A; PIK3CA. Copyright © 2026 Elsevier Inc. All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ## Similar articles * [ Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells. ](https://pubmed.ncbi.nlm.nih.gov/38909932/) Smit DJ, Brauer H, Horn S, Yigit G, Haider MT, Pogenberg V, Schumacher U, Pantel K, Jücker M.Smit DJ, et al.Cell Signal. 2024 Sep;121:111270. doi: 10.1016/j.cellsig.2024.111270. Epub 2024 Jun 21.Cell Signal. 2024.PMID: 38909932 * [ PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. ](https://pubmed.ncbi.nlm.nih.gov/38986734/) Zhang H, Zhang L, He Y, Jiang D, Sun J, Luo Q, Liang H, Wang T, Li F, Tang Y, Yang Z, Liu W, Rao Y, Chen C.Zhang H, et al.Cancer Lett. 2024 Aug 28;598:217112. doi: 10.1016/j.canlet.2024.217112. Epub 2024 Jul 8.Cancer Lett. 2024.PMID: 38986734 * [ PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. ](https://pubmed.ncbi.nlm.nih.gov/23888070/) Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Ho Park B, Lauring J.Beaver JA, et al.Clin Cancer Res. 2013 Oct 1;19(19):5413-22. doi: 10.1158/1078-0432.CCR-13-0884. Epub 2013 Jul 25.Clin Cancer Res. 2013.PMID: 23888070Free PMC article. * [ A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. ](https://pubmed.ncbi.nlm.nih.gov/33213227/) Bertho M, Patsouris A, Augereau P, Robert M, Frenel JS, Blonz C, Campone M.Bertho M, et al.Expert Opin Drug Metab Toxicol. 2021 Feb;17(2):139-152. doi: 10.1080/17425255.2021.1844662. Epub 2020 Dec 8.Expert Opin Drug Metab Toxicol. 2021.PMID: 33213227Review. * [ Alpelisib in the treatment of metastatic HR+ breast cancer with _PIK3CA_ mutations. ](https://pubmed.ncbi.nlm.nih.gov/32964734/) Mavratzas A, Marmé F.Mavratzas A, et al.Future Oncol. 2021 Jan;17(1):13-36. doi: 10.2217/fon-2020-0464. Epub 2020 Sep 23.Future Oncol. 2021.PMID: 32964734Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42341421) ## MeSH terms * Breast Neoplasms* / drug therapy Actions * [ Sea
## Related Clinical Research

- [Breast Self-Examination and Clinical Breast Examination Knowledge and Practice in Buea, Cameroon](https://medichelpline.com/clinical-feed/medrxiv-20-knowledge-and-practice-of-breast-self-examination-and-clinical-breast.md)
- [Causal Multi‑modal AI (CTX) Stratifies Residual Risk and Predicts Everolimus Benefit in Node‑Posit](https://medichelpline.com/clinical-feed/medrxiv-5-a-causal-multi-modal-ai-model-stratifies-residual-risk-and-identifies.md)
- [Targeting the tumour matrisome: advances in ECM biology, diagnostics and therapies](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-understanding-and-targeting-the-tumour-matrisome.md)
- [Structured aerobic exercise linked to lower cancer recurrence and improved survival](https://medichelpline.com/clinical-feed/medical-news-today-0-aerobic-exercise-could-help-improve-outlook-after-cancer-treatment.md)
- [Investigation finds 20 unnecessary mastectomies at County Durham and Darlington trust](https://medichelpline.com/clinical-feed/bmj-2-mastectomy-scandal-twenty-women-had-unnecessary-procedure-at-trust.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.